Skip to Content

Dermira, Inc. (NASDAQ: DERM)

Merger

  • Date:
  • 1/10/2020
  • Company Name:
  • Dermira, Inc.
  • Stock Symbol:
  • DERM
  • Company Name - Buyer:
  • Eli Lilly and Company
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 1/10/2020

Case Finder

Locate any case using the tools below.

NEW YORK, January 10, 2020 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of Dermira, Inc. (NASDAQ: DERM) breached their fiduciary duties or violated the federal securities laws in connection with the company’s proposed sale to Eli Lilly and Company.

On January 10, 2020 Dermira announced that it had signed an agreement to be acquired by Eli Lilly in a deal worth about $1.1 billion. Per the merger agreement Dermira stockholders will receive $18.75 in cash for each share of Dermira common stock owned. The deal is scheduled to close in the first quarter of 2020.

Bragar Eagel & Squire is concerned that Dermira’s board of directors oversaw an unfair process and ultimately agreed to an inadequate deal price. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Dermira stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Dermira. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: